dr. wakelee on rationale to explore osimertinib with concurrent chemotherapy in egfr-mutant nsclc
Published 4 years ago • 180 plays • Length 2:03Download video MP4
Download video MP3
Similar videos
-
1:57
dr. wakelee on benefits of osimertinib in egfr-mutant nsclc treatment
-
1:05
dr. wakelee on recent advancements in egfr-mutant nsclc
-
1:16
dr. wakelee on first-line therapy for egfr-mutant lung cancer
-
2:19
dr. wakelee on detection of egfr t790m mutation in nsclc
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
4:04
treating with osimertinib in egfr-mutated nsclc
-
1:27
dr. wakelee discusses egfr tkis in lung cancer
-
1:53
resistance to osimertinib in egfr-mutated nsclc
-
1:35
dr. herbst on the benefit of adjuvant osimertinib in egfr-mutant nsclc
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
1:29
dr. wakelee on available treatments following tumor progression in lung cancer
-
2:11
dr. low on osimertinib versus dacomitinib in egfr-mutant nsclc
-
2:16
dr. rotow on results of a phase 1/2 trial with osimertinib/gefitinib in egfr-mutant nsclc
-
1:40
dr. piotrowska on eligibility criteria for osimertinib in lung cancer treatment
-
6:06
osimertinib, the standard for egfr nsclc
-
1:53
resistance to osimertinib in egfr-mutated nsclc
-
2:23
dr. zhu on primary resistance to osimertinib in egfr-mutant nsclc
-
2:18
dr. wakelee on first trial to combine antiangiogenesis agents with immunotherapy in nsclc
-
0:50
treating patients with egfr-mutant lung cancer with targeted therapies